TG Therapeutics Inc (TGTX) - Cash Flow Conversion Efficiency
Based on the latest financial reports, TG Therapeutics Inc (TGTX) has a cash flow conversion efficiency ratio of -0.038x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-23.15 Million) by net assets ($607.22 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
TG Therapeutics Inc - Cash Flow Conversion Efficiency Trend (1996–2024)
This chart illustrates how TG Therapeutics Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read TGTX current and long-term liabilities for a breakdown of total debt and financial obligations.
TG Therapeutics Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of TG Therapeutics Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
LegoChem Biosciences Inc
KQ:141080
|
-0.022x |
|
Sinotrans Ltd Class A
SHG:601598
|
0.044x |
|
Sinomach Heavy Equipment Group Co Ltd
SHG:601399
|
-0.020x |
|
Rising Nonferrous Metals Share Co Ltd
SHG:600259
|
0.103x |
|
Shanghai Junshi Biosciences Co Ltd
SHG:688180
|
-0.004x |
|
KURITA WTR IND.UNSP.ADR 2
F:KWI0
|
N/A |
|
LEG Immobilien SE
XETRA:LEG
|
0.017x |
|
Crocs Inc
NASDAQ:CROX
|
0.176x |
Annual Cash Flow Conversion Efficiency for TG Therapeutics Inc (1996–2024)
The table below shows the annual cash flow conversion efficiency of TG Therapeutics Inc from 1996 to 2024. For the full company profile with market capitalisation and key ratios, see how much is TG Therapeutics Inc worth.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $222.36 Million | $-40.52 Million | -0.182x | +6.90% |
| 2023-12-31 | $160.50 Million | $-31.41 Million | -0.196x | +93.49% |
| 2022-12-31 | $58.59 Million | $-176.17 Million | -3.007x | -141.22% |
| 2021-12-31 | $237.15 Million | $-295.63 Million | -1.247x | -201.82% |
| 2020-12-31 | $519.35 Million | $-214.51 Million | -0.413x | +87.99% |
| 2019-12-31 | $38.62 Million | $-132.81 Million | -3.439x | +35.88% |
| 2018-12-31 | $24.04 Million | $-128.93 Million | -5.364x | -- |
| 2017-12-31 | $0.00 | $-93.76 Million | x | -- |
| 2016-12-31 | $0.00 | $-61.59 Million | x | -- |
| 2015-12-31 | $0.00 | $-44.69 Million | x | -- |
| 2014-12-31 | $0.00 | $-35.06 Million | x | -- |
| 2013-12-31 | $0.00 | $-10.82 Million | x | -- |
| 2012-12-31 | $15.55 Million | $-5.19 Million | -0.334x | -3613.31% |
| 2011-12-31 | $9.64 Million | $-86.58K | -0.009x | -102.45% |
| 2010-12-31 | $-5.36 Million | $-1.97 Million | 0.367x | +137.37% |
| 2009-12-31 | $-6.78 Million | $-1.05 Million | 0.155x | -84.76% |
| 2008-12-31 | $-4.38 Million | $-4.44 Million | 1.016x | -91.15% |
| 2007-12-31 | $-891.09K | $-10.23 Million | 11.480x | +322.86% |
| 2006-12-31 | $1.50 Million | $-7.75 Million | -5.151x | -686.97% |
| 2005-12-31 | $9.54 Million | $-6.24 Million | -0.655x | +48.77% |
| 2004-12-31 | $4.45 Million | $-5.69 Million | -1.278x | -152.94% |
| 2003-12-31 | $6.83 Million | $-3.45 Million | -0.505x | -111.53% |
| 2002-12-31 | $-326.99K | $-1.43 Million | 4.381x | +222.37% |
| 2001-12-31 | $1.25 Million | $-4.47 Million | -3.580x | -240.33% |
| 2000-12-31 | $1.10 Million | $-1.15 Million | -1.052x | -55.51% |
| 1999-12-31 | $3.40 Million | $-2.30 Million | -0.676x | -53.51% |
| 1998-12-31 | $5.90 Million | $-2.60 Million | -0.441x | +9.71% |
| 1997-12-31 | $8.40 Million | $-4.10 Million | -0.488x | +74.37% |
| 1996-12-31 | $2.10 Million | $-4.00 Million | -1.905x | -- |
About TG Therapeutics Inc
TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndro… Read more